Novartis Reveals Two Deaths Related to SMA Drug Zolgensma
By Mark Terry,
BioSpace
| 08. 12. 2022
Novartis’ gene therapy for spinal muscular atrophy (SMA) has had a complicated history, of which there is a new chapter. Two patients receiving the therapy have died from acute liver failure, the company reported Thursday.
“While this is important safety information, it is not a new safety signal and we firmly believe in the overall favorable risk/benefit profile of Zolgensma, which to date has been used to treat more than 2,300 patients worldwide across clinical trials, managed access programs and in the commercial setting,” Novartis stated in a press release.
Novartis reported that the children developed acute liver failure about five to six weeks after receiving Zolgensma and about 1-10 days after initiation of corticosteroid taper. The corticosteroids are used to help manage risk from the therapy. The cases were in Russia and Kazakhstan.
The company indicated it has notified regulators in all countries where the therapy is approved and will inform healthcare providers where it is allowed. The company also plans to update the Zolgensma label to include mention of the deaths.
SMA is...
Related Articles
By Carl Zimmer, The New York Times | 06.04.2026
Scientists at Columbia University have edited the DNA of early human embryos with unprecedented accuracy, an achievement that could open the way to babies engineered with particular characteristics.
The prospect has fueled controversy for years. On the one hand, the...
Faster, Higher, Stronger was the Olympic motto from 1874 until 2001, when “ – Together” was added, to stress the “moral and educational perspective” of the Games. The folks who paid for or participated in the Enhanced Games – the name itself a nod to the Olympics – held in Las Vegas on Sunday, May 24, apparently use a different edit:
Faster, Higher, Stronger with Chemistry
High-level sport draws huge crowds. Coming very soon, the soccer World Cup, featuring...
By Gina Kolata, The New York Times | 05.25.2026
In a small, preliminary study, an experimental gene-editing treatment dramatically lowered cholesterol levels, perhaps permanently, after just one infusion, scientists reported on Monday.
If confirmed in larger studies, researchers hope the findings may lead to a one-and-done way to prevent...
By Ryan Cross, Endpoint News | 05.20.2026
BOSTON — Over the past year, I’ve begun hearing rumblings from scientists who secretly think it’s time to stop being stodgy about editing the genes of human embryos.
For the most part, they are still too timid to speak up...
